+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Biosimilars Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Pre Book Price: $ 5216

Original Price: $ 5795

TABLE OF CONTENTS
 
1) INTRODUCTION
 1.1 Objective of the Research
 1.2 Report Highlights
 1.3 Scope of the Report
 1.4 Research Methodology
 
2) MARKET OUTLINE
2.1. Defining the global biosimilar market
2.2. Driving factor analysis
2.2.1. Demand and Supply-side drivers
2.2.2. Restraints & opportunities
2.2.3. Key points
2.3. Issues related with biosimilar
2.4. Potential matrix for global biosimilar 
2.4.1. Products
2.4.2. Applications
2.5. Biosimilar market dynamics
2.6. Pricing of biosimilar drug
2.7. Biosimilar products geographical trend
 
3) BIOSIMILAR PRODUCTS MARKET
3.1. Recombinant glycosylated proteins
3.1.1. Drivers & restraints
3.1.2. Erythropoietin (EPO)
3.1.3. Urokinase
3.1.4. Glucocerebrosidase
3.1.5. Monoclonal antibodies
3.1.5.1. Chimaeric antibodies
3.1.5.2. Humanized / cdr-grafted / reshaped antibodies
3.1.5.3. Human antibodies and fusion protein
3.1.6. Follitropin
3.1.7. Thyrotropin
3.1.8. Becaplermin
3.1.9. Granulocyte-macrophage-CSF (GM-CSF)
3.1.10. Recombinant Human DNASE (RHDNASE)
3.1.11. Factor VIIA
3.1.11.1. Factor VIII
3.1.11.2. Factor IX
3.1.12. Activated protein-c
3.1.13. Tissue plasminogen activator
3.2. Recombinant non-glycosylated protein
3.2.1. Drivers and restraints
3.2.2. Insulin
3.2.2.1. Drivers & restraints
3.2.2.2. Opportunities
3.2.3. Interferons
3.2.3.1. Interferon alfa
3.2.3.2. Interferon beta-1a
3.2.3.3. Interferon gamma
3.2.4. Recombinant human growth hormone
3.2.5. Lepirudin
3.2.6. Interleukin-11
3.2.7. Anakinra
3.2.8. Interleukin – 2 (Il-2)
3.2.9. Granulocyte colony-stimulating factor (G-CSF)
3.3. Peptides
3.3.1. Drivers
3.3.2. Restraints & opportunities
3.3.3. Cyclosporine
3.3.4. Calcitonin
3.3.5. Bivalirudin
3.3.6. Enfuvirtide
3.3.7. Glucagon
3.3.8. Eptifibatide
3.3.9. Octreotide
3.3.10. Desmopressin
3.3.11. LH-RH (Leuprolide)
3.3.12. Nesiritide
3.3.13. Teriparatide
 
4) BIOSIMILAR TECHNOLOGY
4.1. Recombinant DNA technology (RDNA technology)
4.1.1. Drivers
4.1.2. Restraints & opportunities
4.2. Chromatography
4.2.1. Drivers & opportunities
4.2.2. Top player analysis
4.2.3. Liquid chromatography (LC)
4.2.4. Gas chromatography (GC)
4.3. Bioassay
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Techniques in bioassay
4.3.3.1. Six point assay
4.3.3.2. Multiple point assays
4.3.3.3. Interpolation method
4.3.3.4. Bracketing method
4.3.3.5. Matching bioassays
4.4. Monoclonal antibodies (MAB) technology
4.4.1. Drivers
4.4.2. Restraints & opportunities
4.4.3. Top player analysis
4.5. Western blotting
4.5.1. Drivers
4.5.2. Restraints & opportunities
4.6. Protein sequencing
4.6.1. Drivers
4.6.2. Restraints & opportunities
4.7. Nuclear magnetic resonance (NMR) technology
4.7.1. Drivers
4.7.2. Restraints & opportunities
4.8. Electrophoresis
4.8.1. Drivers
4.8.2. Restraints & opportunities
4.8.3. GEL electrophoresis
4.8.4. Capillary electrophoresis
4.9. Mass spectrometry
4.9.1. Drivers
4.9.2. Restraints
 
5) BIOSIMILAR APPLICATION MARKET
5.1. Introduction
5.1.1. Drivers
5.1.2. Restraints
5.2. Oncology
5.2.1. Drivers
5.2.2. Restraints & opportunities
5.2.3. Lung cancer
5.2.4. Colorectal cancer
5.2.5. Breast cancer
5.2.6. Cervical cancer
5.2.7. Leukemia
5.2.7.1. Drivers
5.2.8. Prostate cancer
5.3. Infectious diseases
5.3.1. HIV/Aids
5.3.1.1. Drivers
5.3.2. Hepatitis B
5.3.3. Hepatitis C
5.4. Chronic and autoimmune diseases
5.4.1. Diabetes
5.4.1.1. Drivers
5.4.2. Neutropenia
5.4.3. Multiple sclerosis
5.4.3.1. Drivers
5.4.3.2. Inhibitors and opportunities
5.4.4. Cystic fibrosis
5.4.5. Rheumatoid arthritis (RA)
5.4.5.1. Drivers
5.4.5.2. Restraints
5.4.6. Acromegaly
5.4.6.1. Driver
5.4.7. Leprosy
5.5. Hematology
5.5.1. Drivers
5.5.2. Chemotherapy induced anemia
5.5.2.1. Drivers
5.5.2.2. Restraints and opportunities
5.5.3. Hemophilia
5.5.4. Pulmonary embolism
5.5.4.1. Drivers
5.6. Growth hormone deficiency (GHD)
5.6.1. Drivers
5.7. Other diseases
5.7.1. Gaucher disease
5.7.2. Osteoporosis
5.7.3. Fertility disorders (Infertility)
5.7.4. Skin ulcer
5.7.5. Hypoglycemia
5.7.6. Nocturnal enuresis
5.7.7. Congestive heart failure (CHF)
5.7.8. Systemic sepsis
5.7.9. Others
 
6) BIOSIMILAR SERVICE MARKET
6.1. Clinical trials
6.1.1. Drivers & restraints
6.1.2. Phase I
6.1.3. Phase II
6.1.4. Phase III
6.2. Contract research and manufacturing services
6.2.1. Drivers
6.2.2. Restraints & opportunities
 
7) GEOGRAPHIC ANALYSIS
7.1. North America biosimilar market
7.2. EMEA biosimilar market
7.3. Asia-Pacific biosimilar market
7.4. Latin America Biosimilars market
 
8) COMPANY PROFILES
8.1.1. Teva
8.1.2. Sandoz
8.1.3. Hospira
8.1.4. Mylan
8.1.5. Actavis
8.1.6. Biocon Ltd.
8.1.7. Cipla Ltd.
8.1.8. Dr. Reddy\'s Laboratories Ltd.
8.1.9. Wockhardt Ltd
8.1.10. Stada Arzneimittel AG

Global Biosimilars Market: Overview

The global market for biosimilars is projected to grow at a significant rate in the coming few years, owing to the low cost of these products. With the growing focus on research and development activities, the market is expected to generate promising opportunities in the next few years.

The research study offers a thorough overview of the global biosimilars market, providing understanding into the major factors that are projected to affect the development of the market in the next few years. The segmentation of the global biosimilars market with the help of analytical tools helps the readers and market players in attaining a strong understanding of the overall market. Furthermore, the growth drivers, restraints, current trends, opportunities, and the limitations in the market have been discussed in the research report.

Global Biosimilars Market: Drivers and Barriers

The emergence of off-patent biologic products is one of the major factors anticipated to encourage the growth of the global biosimilars market in the next few years. These drugs are comparatively cost-effective, owing to which the demand is expected to increase substantially in the next few years. In addition, the growing prevalence of different ailments across the globe is predicted to fuel the growth of the market.

On the other hand, the innovative strategies that have been devised by biologic drug manufacturers are estimated to curb the development of the global biosimilars market, especially the new entrants of the market. Furthermore, the global biosimilars market is expected to witness several challenges throughout the forecast period. The need for a complex infrastructure for the production of biosimilars and the lengthy clinical trials required to attain the approval from the regulatory bodies are some of the important factors likely to restrict the growth of the global market in the next few years.

Global Biosimilars Market: Regional Outlook

From a geographical viewpoint, Europe is expected to lead the global biosimilars market and account for a large share in the next few years. The high growth of this region can be attributed to the presence of several biosimilar drugs including, binocrits, tevagrastim, and omnitrope. In addition, the strict regulatory framework and the rising products in the pipeline are estimated to contribute substantially towards the development of the Europe biosimilars market in the next few years.

Furthermore, the promising opportunities for the key players in the developing economies are estimated to encourage the growth of the biosimilars market in Asia Pacific in the next few years. As per the research study, this region is expected to register a progressive growth rate in the near future. On the other hand, the stringent government regulations in the U.S. are projected to restrict the growth of the North America market.

Companies Mentioned in the Research Report

Some of the leading players operating in the biosimilars market across the globe are Genentech, Ranbaxy Laboratories, Sandoz, Bristol-Myers Squibb, Cipla, Abbott, and Astra Zeneca. The growing focus of technological developments in the global market and the notable efforts taken by the leading players are some of the factors likely to supplement the growth of the global market in the next few years. The increasing level of competition owing to the growing participation of players is predicted to encourage the market growth in the coming years.

The research study has offered a complete overview of the competitive scenario of the global biosimilars market. The company profiles, recent developments, financial overview, and SWOT analysis of the leading players have been provided in the study. In addition, the business policies and marketing tactics that are being used by these players have been highlighted to provide a clear picture of the market.

The global biosimilars market has been segmented as:

Global Biosimilars Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments


Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.


To receive discount, please click on the button below.

Please click on the button below to customize this report.

 
 
Back To Top